Investments
2Portfolio Exits
1
Want to inform investors similar to Harbinger/Aurora Venture Fund about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Harbinger/Aurora Venture Fund Investments
2 Investments
Harbinger/Aurora Venture Fund has made 2 investments. Their latest investment was in CoImmune as part of their Debt - II on September 9, 2010.
Harbinger/Aurora Venture Fund Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/13/2010 | Debt - II | CoImmune | $4.85M | No | AAC Capital Partners, Aurora Funds, BD Ventures, CDP Capital, Cordova Ventures, Forbion Capital Partners, GeneChem Therapeutics Venture Fund, Harbinger/Aurora Venture Fund, InterSouth Partners, Japan Asia Investment Group, Kirin Pharma Company, Lumira Ventures, Mizuho Capital, Morningside Ventures, Oakwood Medical Investors, Pacific Horizon Ventures, Sanders Morris Harris Private Equity, Senmed Medical Ventures, Signet Healthcare Partners, Sutter Hill Ventures, TFG Capital Unternehmensbeteiligungsgesellschaft, TVM Capital Life Science, and Vestcorp AG | |
9/19/2001 | Series B |
Date | 9/13/2010 | 9/19/2001 |
|---|---|---|
Round | Debt - II | Series B |
Company | CoImmune | |
Amount | $4.85M | |
New? | No | |
Co-Investors | AAC Capital Partners, Aurora Funds, BD Ventures, CDP Capital, Cordova Ventures, Forbion Capital Partners, GeneChem Therapeutics Venture Fund, Harbinger/Aurora Venture Fund, InterSouth Partners, Japan Asia Investment Group, Kirin Pharma Company, Lumira Ventures, Mizuho Capital, Morningside Ventures, Oakwood Medical Investors, Pacific Horizon Ventures, Sanders Morris Harris Private Equity, Senmed Medical Ventures, Signet Healthcare Partners, Sutter Hill Ventures, TFG Capital Unternehmensbeteiligungsgesellschaft, TVM Capital Life Science, and Vestcorp AG | |
Sources |
Harbinger/Aurora Venture Fund Portfolio Exits
1 Portfolio Exit
Harbinger/Aurora Venture Fund has 1 portfolio exit. Their latest portfolio exit was CoImmune on February 07, 2014.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.